市場調查報告書

濾泡型淋巴瘤:至2030年的流行病學預測

Follicular Lymphoma - Epidemiology Forecast to 2030

出版商 DelveInsight Business Research LLP 商品編碼 955865
出版日期 內容資訊 英文 100 Pages
商品交期: 最快1-2個工作天內
價格
濾泡型淋巴瘤:至2030年的流行病學預測 Follicular Lymphoma - Epidemiology Forecast to 2030
出版日期: 2020年07月01日內容資訊: 英文 100 Pages
簡介

本報告提供美國、德國、法國、義大利、西班牙、英國、日本的主要7個國家的至2030年的濾泡型淋巴瘤的流行病學展望調查,SWOT分析,疾病的背景和概要,流行病學患者數,各國流行病學,治療方法,指南,未支援的需求,病人歷程,病例等資訊。

目錄

第1章 主要調查結果

第2章 摘要整理

第3章 SWOT分析

第4章 疾病的背景和概要

  • 簡介
  • 濾泡型淋巴瘤的種類
  • 徵兆與症狀
  • 原因
  • 階段和等級的判斷
  • 遺傳性的情形
  • 病理生理學
  • 診斷

第5章 流行病學和患者人口

  • 主要調查結果
  • 主要7個國家的患者數

第6章 各國流行病學

  • 前提和根據-主要7個國家
  • 美國
    • 總患者數
    • 各等級的患者數
    • 各年齡的患者數
    • 各階段患者數
  • 歐洲5個國家
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第7章 治療方法

第8章 指南

  • NCCN的指南
  • ESMO的指南
  • 日本血液學會(JSH)的指南

第9章 未支援的需求

第10章 相關組織

第11章 病人歷程

  • 症狀的進展
  • 一般的病人歷程

第12章 病例報告

  • 患者的案例研究:從濾泡型淋巴瘤到DLBCL
  • 診斷的精密檢驗
  • 免疫球蛋白重鏈和輕鏈介入的病例

第13章 附錄

  • 參考文件
  • 調查手法

第14章 DelveInsight的服務內容

第15章 免責聲明

第16章 關於DelveInsight

目錄
Product Code: DIEI1016

DelveInsight's 'Follicular Lymphoma - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical, and forecasted Follicular Lymphoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Follicular Lymphoma: Understanding

The DelveInsight's Follicular Lymphoma epidemiology report gives a thorough understanding of the Follicular Lymphoma by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Follicular Lymphoma in the US and Europe. Moreover, the report covers the detailed information of the Follicular Lymphoma scenario in seven major countries (US, EU5, and Japan).

Epidemiology Perspective by DelveInsight

This section encompassing Follicular Lymphoma epidemiology provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Follicular Lymphoma epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. This segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Detailed Epidemiology Segmentation

The Follicular Lymphoma epidemiology covered in the report provides historical as well as forecasted Follicular Lymphoma epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:

  • The Follicular Lymphoma report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.
  • The Follicular Lymphoma report and model provide an overview of the global trends of Follicular Lymphoma in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report provides insight into the historical and forecasted patient pool of Follicular Lymphoma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
  • The report helps recognize the growth opportunities in the 7MM concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of Follicular Lymphoma.
  • The report provides the segmentation of the Follicular Lymphoma epidemiology.

Report Highlights:

  • 11-year Forecast of Follicular Lymphoma Epidemiology
  • 7MM Coverage
  • Incident cases of Follicular Lymphoma
  • Grade-specific Cases of Follicular Lymphoma
  • Incidence of Follicular Lymphoma by Age
  • Stage-specific Cases of Follicular Lymphoma

KOL Views

We interview KOLs and include SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. It will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM concerning the patient population pertaining to Follicular Lymphoma?
  • What are the key findings pertaining to the Follicular Lymphoma epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Follicular Lymphoma across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of Follicular Lymphoma?
  • What are the currently available treatments of Follicular Lymphoma?

Reasons to buy:

The Follicular Lymphoma Epidemiology report will allow the user to:

  • Develop business strategies by understanding the trends shaping and driving the global Follicular Lymphoma market.
  • Quantify patient populations in the global Follicular Lymphoma market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Follicular Lymphoma therapeutics in each of the markets covered
  • Understand the magnitude of Follicular Lymphoma population by its epidemiology
  • The Follicular Lymphoma Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Executive Summary of Follicular Lymphoma

3. SWOT Analysis for Follicular Lymphoma

4. Disease Background and Overview

  • 4.1. Introduction
  • 4.2. Types of Follicular Lymphoma
  • 4.3. Sign and Symptoms
  • 4.4. Causes
  • 4.5. Staging and Grading
  • 4.6. Genetic Landscape of Follicular Lymphoma
  • 4.7. Pathophysiology
  • 4.8. Diagnosis

5. Epidemiology and Patient Population

  • 5.1. Key Findings
  • 5.2. 7MM Total Incident Patient Population of Follicular Lymphoma

6. Country Wise-Epidemiology of Follicular Lymphoma

  • 6.1. Assumptions and Rationale - 7MM
  • 6.2. The United States
    • 6.2.1. Total Incident Cases of Follicular Lymphoma in the United States
    • 6.2.2. Grade-specific Cases of Follicular Lymphoma in the United States
    • 6.2.3. Age-specific Cases of Follicular Lymphoma in the United States
    • 6.2.4. Stage-specific Cases of Follicular Lymphoma in the United States
  • 6.3. EU5
    • 6.3.1. Germany
      • 6.3.1.1. Total Incident Cases of Follicular Lymphoma in Germany
      • 6.3.1.2. Grade-specific Cases of Follicular Lymphoma in Germany
      • 6.3.1.3. Age-specific Cases of Follicular Lymphoma in Germany
      • 6.3.1.4. Stage-specific Cases of Follicular Lymphoma in Germany
    • 6.3.2. France
      • 6.3.2.1. Total Incident Cases of Follicular Lymphoma in France
      • 6.3.2.2. Grade-specific Cases of Follicular Lymphoma in France
      • 6.3.2.3. Age-specific Cases of Follicular Lymphoma in France
      • 6.3.2.4. Stage-specific Cases of Follicular Lymphoma in France
    • 6.3.3. Italy
      • 6.3.3.1. Total Incident Cases of Follicular Lymphoma in Italy
      • 6.3.3.2. Grade-specific Cases of Follicular Lymphoma in Italy
      • 6.3.3.3. Age-specific Cases of Follicular Lymphoma in Italy
      • 6.3.3.4. Stage-specific Cases of Follicular Lymphoma in Italy
    • 6.3.4. Spain
      • 6.3.4.1. Total Incident Cases of Follicular Lymphoma in Spain
      • 6.3.4.2. Grade-specific Cases of Follicular Lymphoma in Spain
      • 6.3.4.3. Age-specific Cases of Follicular Lymphoma in Spain
      • 6.3.4.4. Stage-specific Cases of Follicular Lymphoma in Spain
    • 6.3.5. The United Kingdom
      • 6.3.5.1. Total Incident Cases of Follicular Lymphoma in the United Kingdom
      • 6.3.5.2. Grade-specific Cases of Follicular Lymphoma in the United Kingdom
      • 6.3.5.3. Age-specific Cases of Follicular Lymphoma in the UK
      • 6.3.5.4. Stage-specific Cases of Follicular Lymphoma in the UK
  • 6.4. Japan
    • 6.4.1. Total Incident Cases of Follicular Lymphoma in Japan
    • 6.4.2. Grade-specific Cases of Follicular Lymphoma in Japan
    • 6.4.3. Age-specific Cases of Follicular Lymphoma in Japan
    • 6.4.4. Stage-specific Cases of Follicular Lymphoma in Japan

7. Treatment

8. Guidelines

  • 8.1. NCCN Guidelines for Patient with Follicular Lymphoma
  • 8.2. ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up: Newly diagnosed and relapsed follicular lymphoma
  • 8.3. Japanese Society of Hematology (JSH) practical guidelines for Follicular lymphoma

9. Unmet Needs

10. Organizations contributing toward Follicular Lymphoma

11. Patient Journey

  • 11.1. A Journey through follicular lymphoma
  • 11.2. Patient Journey: General

12. Case Reports

  • 12.1. Patient Case Study: From Follicular Lymphoma to DLBCL
  • 12.2. Diagnostic Workup for Follicular Lymphoma
  • 12.3. A case study of t(14;22)(q32;q11) involving immunoglobulin heavy and light chain in follicular lymphoma

13. Appendix

  • 13.1. Bibliography
  • 13.2. Report Methodology

14. DelveInsight Capabilities

15. Disclaimer

16. About DelveInsight

List of Tables

  • Table 1: Summary of Follicular Lymphoma Epidemiology, and Key Events (2017-2030)
  • Table 2: Prognostic Factors Associated with Follicular Lymphoma
  • Table 3: Staging of Non-Hodgkin Lymphoma
  • Table 4: Biological Factors Associated with Follicular Lymphoma Transformation
  • Table 5: Incident Patient Population of Follicular Lymphoma in 7MM (2017-2030)
  • Table 6: Total Incident Cases of Follicular Lymphoma in the United States (2017-2030)
  • Table 7: Grade-specific Cases of Follicular Lymphoma in the United States (2017-2030)
  • Table 8: Age-specific Cases of Follicular Lymphoma in the United States (2017-2030)
  • Table 9: Stage-specific Cases of Follicular Lymphoma in the United States (2017-2030)
  • Table 10: Total Incident Cases of Follicular Lymphoma in Germany (2017-2030)
  • Table 11: Grade-specific Cases of Follicular Lymphoma in Germany (2017-2030)
  • Table 12: Age-specific Cases of Follicular Lymphoma in Germany (2017-2030)
  • Table 13: Stage-specific Cases of Follicular Lymphoma in Germany (2017-2030)
  • Table 14: Total Incident Cases of Follicular Lymphoma in France (2017-2030)
  • Table 15: Grade-specific Cases of Follicular Lymphoma in France (2017-2030)
  • Table 16: Age-specific Cases of Follicular Lymphoma in France (2017-2030)
  • Table 17: Stage-specific Cases of Follicular Lymphoma in France (2017-2030)
  • Table 18: Total Incident Cases of Follicular Lymphoma in Italy (2017-2030)
  • Table 19: Grade-specific Cases of Follicular Lymphoma in Italy (2017-2030)
  • Table 20: Age-specific Cases of Follicular Lymphoma in Italy (2017-2030)
  • Table 21: Stage-specific Cases of Follicular Lymphoma in Italy (2017-2030)
  • Table 22: Total Incident Cases of Follicular Lymphoma in Spain (2017-2030)
  • Table 23: Grade-specific Cases of Follicular Lymphoma in Spain (2017-2030)
  • Table 24: Age-specific Cases of Follicular Lymphoma in Spain (2017-2030)
  • Table 25: Stage-specific Cases of Follicular Lymphoma in Spain (2017-2030)
  • Table 26: Total Incident Cases of Follicular Lymphoma in the United Kingdom (2017-2030)
  • Table 27: Grade-specific Cases of Follicular Lymphoma in the United Kingdom (2017-2030)
  • Table 28: Age-specific Cases of Follicular Lymphoma in the UK (2017-2030)
  • Table 29: Stage-specific Cases of Follicular Lymphoma in the UK (2017-2030)
  • Table 30: Total Incident Cases of Follicular Lymphoma in Japan (2017-2030)
  • Table 31: Grade-specific Cases of Follicular Lymphoma in Japan (2017-2030)
  • Table 32: Age-specific Cases of Follicular Lymphoma in Japan (2017-2030)
  • Table 33: Stage-specific Cases of Follicular Lymphoma in Japan (2017-2030)
  • Table 34: Organizations contributing toward Follicular Lymphoma

List of Figures

  • Figure 1: SWOT Analysis
  • Figure 2: Origin of B-cell Lymphomas
  • Figure 3: Grading of follicular lymphoma
  • Figure 4: Ann Arbor Classification
  • Figure 5: Transformation in Follicular Lymphoma
  • Figure 6: Pathogenesis of Follicular Lymphoma
  • Figure 7: Stepwise Evolution of Follicular Lymphoma
  • Figure 8: Model of Microenvironment in Follicular Lymphoma
  • Figure 9: Transformation in Follicular Lymphoma
  • Figure 10: Incident Patient Population of Follicular Lymphoma in 7MM (2017-2030)
  • Figure 11: Total Incident Cases of Follicular Lymphoma in the United States (2017-2030)
  • Figure 12: Grade-specific Cases of Follicular Lymphoma in the United States (2017-2030)
  • Figure 13: Age-specific Cases of Follicular Lymphoma in the United States (2017-2030)
  • Figure 14: Stage-specific Cases of Follicular Lymphoma in the United States (2017-2030)
  • Figure 15: Total Incident Cases of Follicular Lymphoma in Germany (2017-2030)
  • Figure 16: Grade-specific Cases of Follicular Lymphoma in Germany (2017-2030)
  • Figure 17: Age-specific Cases of Follicular Lymphoma in Germany (2017-2030)
  • Figure 18: Stage-specific Cases of Follicular Lymphoma in Germany (2017-2030)
  • Figure 19: Total Incident Cases of Follicular Lymphoma in France (2017-2030)
  • Figure 20: Grade-specific Cases of Follicular Lymphoma in France (2017-2030)
  • Figure 21: Age-specific Cases of Follicular Lymphoma in France (2017-2030)
  • Figure 22: Stage-specific Cases of Follicular Lymphoma in France (2017-2030)
  • Figure 23: Total Incident Cases of Follicular Lymphoma in Italy (2017-2030)
  • Figure 24: Grade-specific Cases of Follicular Lymphoma in Italy (2017-2030)
  • Figure 25: Age-specific Cases of Follicular Lymphoma in Italy (2017-2030)
  • Figure 26: Stage-specific Cases of Follicular Lymphoma in Italy (2017-2030)
  • Figure 27: Total Incident Cases of Follicular Lymphoma in Spain (2017-2030)
  • Figure 28: Grade-specific Cases of Follicular Lymphoma in Spain (2017-2030)
  • Figure 29: Age-specific Cases of Follicular Lymphoma in Spain (2017-2030)
  • Figure 30: Stage-specific Cases of Follicular Lymphoma in Spain (2017-2030)
  • Figure 31: Total Incident Cases of Follicular Lymphoma in the United Kingdom (2017-2030)
  • Figure 32: Grade-specific Cases of Follicular Lymphoma in the United Kingdom (2017-2030)
  • Figure 33: Age-specific Cases of Follicular Lymphoma in the UK (2017-2030)
  • Figure 34: Stage-specific Cases of Follicular Lymphoma in the UK (2017-2030)
  • Figure 35: Total Incident Cases of Follicular Lymphoma in Japan (2017-2030)
  • Figure 36: Grade-specific Cases of Follicular Lymphoma in Japan (2017-2030)
  • Figure 37: Age-specific Cases of Follicular Lymphoma in Japan (2017-2030)
  • Figure 38: Stage-specific Cases of Follicular Lymphoma in Japan (2017-2030)
  • Figure 39: High tumor burden criteria in FL [Groupe d'Etude des Lymphomes Folliculaires (GELF)]
  • Figure 40: Follicular Lymphoma-specific International Prognostic Index' (FLIPI) risk factors
  • Figure 41: Treatment Algorithm
  • Figure 42: Standard first-line therapy of Follicular Lymphoma
  • Figure 43: Overview of evidence-based staging, prognostic tools and strategies and treatment of FL
  • Figure 44: Follow-up Care for FL
  • Figure 45: Guidelines for Follicular Lymphoma
  • Figure 47: Unmet Needs of Follicular Lymphoma